Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma (SOGUG-TIVOREAL)

Spanish Oncology Genito-Urinary Group

Status: Completed

Conditions: Renal Cell Cancer Metastatic

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT07354282

SOGUG-2024-IEC(REN)-1

Details and patient eligibility

About

The SOGUG-TIVOREAL study is a retrospective observational study with medications.

This study is based on the retrospective collection of data from patients who have been treated with Tivozanib as first-line therapy between 03/01/2019 and 08/31/2024 for metastatic renal cell carcinoma (mRCC).

Enrollment: 200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. - Patients ≥ 18 years old.
2. - Who have signed the informed consent form, except for patients who were deceased at the time of inclusion.
3. - Histological diagnosis of stage IV clear cell renal carcinoma.
4. - Who started treatment with Tivozanib as first-line therapy between March 1, 2019, and August 31, 2024.
5. - Who received treatment at the participating center.

Exclusion criteria

1. - Patients previously treated at another center who were later referred to one of the participating centers. In this case, the patient will be included in the center where the treatment was initiated.
2. - Explicit objection by the subject or their legal representative to participate in the study.